Your AI-Trained Oncology Knowledge Connection!

Post-Conference Perspectives: CD19-directed CAR-T Cell Therapy in Lymphomas : Episode 6

Video

February 13, 2023

Available Treatment Options for Relapsed/Refractory Follicular Lymphoma (R/R FL)

Author(s):

Loretta J. Nastoupil, MD,Marc S. Hoffmann, MD

Dr Marc S Hoffman reviews the currently available treatment options for relapsed/refractory follicular lymphoma.

EP: 1.Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

EP: 2.Currently Available Treatment Options for Patients With R/R DLBCL

EP: 3.ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL

EP: 4.Is There a Potential Role for Rapcabtagene Autoleucel in R/R LBCL?

EP: 5.Selecting the Appropriate CAR T-Cell Therapy for Patients with R/R LBCL

Now Viewing

EP: 6.Available Treatment Options for Relapsed/Refractory Follicular Lymphoma (R/R FL)

EP: 7.CAR T-Cell Therapy for Patients With R/R FL

EP: 8.Utilizing CAR T-Cell Therapy in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All

Video

Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge

May 14th 2025 - May 15th 2026

online-activity

Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Arizona

May 13th 2025 - Jun 18th 2025

online-activity

Video

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

May 9th 2025 - Jun 14th 2025

online-activity

Latest Conference Coverage

OncLive Polls Spotlight Phase 3 Breast Cancer Studies Generating Buzz Ahead of ASCO 2025

Ribociclib/Endocrine Therapy Yields Similar pCRs Compared With Chemotherapy in HR+ Early Breast Cancer

Emiltatug Ledadotin Shows Early Clinical Activity and Safety in Advanced/Metastatic TNBC

Puxitatug Samrotecan Yields Responses With Manageable Safety in Pretreated HR+/HER2– Advanced Breast Cancer

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

Available Treatment Options for Relapsed/Refractory Follicular Lymphoma (R/R FL)

EP: 1.Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

EP: 2.Currently Available Treatment Options for Patients With R/R DLBCL

EP: 3.ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL

EP: 4.Is There a Potential Role for Rapcabtagene Autoleucel in R/R LBCL?

EP: 5.Selecting the Appropriate CAR T-Cell Therapy for Patients with R/R LBCL

EP: 6.Available Treatment Options for Relapsed/Refractory Follicular Lymphoma (R/R FL)

EP: 7.CAR T-Cell Therapy for Patients With R/R FL

EP: 8.Utilizing CAR T-Cell Therapy in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Newsletter

Latest CME

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

Proactive Adverse Event Management for HER2+ BTC Treatments

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Arizona

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

Proactive Adverse Event Management for HER2+ BTC Treatments

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Arizona

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

Proactive Adverse Event Management for HER2+ BTC Treatments

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

Latest Conference Coverage